Department of Internal Medicine, Division of Medical Oncology, The Ohio State University, Columbus, OH, USA.
Department of Internal Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Curr Urol Rep. 2019 Aug 29;20(10):56. doi: 10.1007/s11934-019-0932-2.
The clinical role of fluorine-18 fluoro-2-deoxyglucose (FDG)-positron emission tomography (PET) in renal cell carcinoma (RCC) is still evolving. Use of FDG PET in RCC is currently not a standard investigation in the diagnosis and staging of RCC due to its renal excretion. This review focuses on the clinical role and current status of FDG PET and PET/CT in RCC.
Studies investigating the role of FDG PET in localized RCC were largely disappointing. Several studies have demonstrated that the use of hybrid imaging PET/CT is feasible in evaluating the extra-renal disease. A current review of the literature determines PET/CT to be a valuable tool both in treatment decision-making and monitoring and in predicting the survival in recurrent and metastatic RCC. PET/CT might be a viable option in the evaluation of RCC, especially recurrent and metastatic disease. PET/CT has also shown to play a role in predicting survival and monitoring therapy response.
氟-18 氟代-2-脱氧葡萄糖（FDG）-正电子发射断层扫描（PET）在肾细胞癌（RCC）中的临床作用仍在不断发展。由于 FDG 经肾脏排泄，FDG PET 在 RCC 的诊断和分期中的应用目前不是标准检查。本综述重点介绍 FDG PET 和 PET/CT 在 RCC 中的临床作用和现状。
研究 FDG PET 在局限性 RCC 中的作用的研究结果大多令人失望。几项研究表明，使用混合成像 PET/CT 评估肾外疾病是可行的。目前对文献的回顾确定，PET/CT 是一种在治疗决策、监测和预测复发性和转移性 RCC 生存方面都有价值的工具。PET/CT 可能是评估 RCC 的一种可行选择，尤其是复发性和转移性疾病。PET/CT 也已显示出在预测生存和监测治疗反应方面的作用。
